- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 18, Issue 5, 2012
Current Pharmaceutical Design - Volume 18, Issue 5, 2012
Volume 18, Issue 5, 2012
-
-
Editorial [Hot Topic: New Developments in Pharmaceutical Treatments for Cystic Fibrosis (Executive Guest Editor: Hartmut Grasemann)]
More LessCystic fibrosis (CF) is an inherited disease of impaired epithelial transmembrane ion transport which is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Conventional treatment strategies for CF lung disease, the major contributor to morbidity and mortality in patients with CF, are predominantly symptomatic and do not address the underlying defects. A better understanding of the Read More
-
-
-
New Therapies in Cystic Fibrosis
Authors: Felix Ratjen and Hartmut GrasemannCystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that lead to abnormalities in transepithelial ion transport in the airways of affected patients. Lung disease is the major contributor to morbidity and mortality in patients with cystic fibrosis but recommended therapeutic interventions so far have focussed on symptom control rather than treatment of the under Read More
-
-
-
Identification and Validation of Hits from High Throughput Screens for CFTR Modulators
Authors: Stan Pasyk, Steven Molinski, Wilson Yu, Paul D.W. Eckford and Christine E. BearThese are exciting times with the appearance of small molecule compounds in clinical trials which target the basic defects caused by mutation in the CFTR gene. This progress was enabled by years of basic research probing the molecular and cellular consequences caused by mutation and the development of methods by which to study the primary anion transport defect in a high-throughput manner by robotics. Future progress Read More
-
-
-
Progress in Gene and Cell Therapy for Cystic Fibrosis Lung Disease
Authors: Uta Griesenbach and Eric W.F.W. AltonAlthough the development of gene therapy for cystic fibrosis (CF) was high priority for many groups in academia and industry in the first 10 to 15 years after cloning the gene, more recently active research into CF gene therapy is only being performed by a small number of committed, mainly academic, groups. However, despite the waning enthusiasm, which is largely due to the realisation that gene transfer into lungs is more Read More
-
-
-
Early In Vivo Testing to Assess New Therapeutic Interventions in CF Patients
By Tanja GonskaNew therapeutic strategies are targeting correction of the basic defect in cystic fibrosis (CF) disease. In fact, completion of the first successful clinical drug trials now signals the start of a new era in CF therapy. Many promising drug candidates are emerging into the clinical drug pipeline. However, their translation from the bench to the bed side is challenged by the lack of accurate and reliable biomarker assays that allow Read More
-
-
-
Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
More LessSince the discovery of the CFTR gene mutations which cause cystic fibrosis (CF) in 1989 the average life expectancy of CF patients has almost doubled and now exceeds 37 years. The advances in molecular diagnostics and medical treatments expanded beyond the CF patient population as some of the newest treatments are also being tested for treatment of complex diseases such as COPD and other inherited disorders. Ra Read More
-
-
-
New Developments in Inhaled Antibiotics for the Treatment of Pseudomonas aeruginosa
More LessThe field of inhaled antibiotics that target Pseudomonas aeruginosa infections has made substantial contributions to the health, disease management, and life expectancies of individuals with cystic fibrosis (CF) over the last three decades [1-3]. This paper reviews some of the recent clinical developments in the field of inhaled antibiotics for CF and briefly describes formulations and ongoing developments for US and/o Read More
-
-
-
New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
More LessThe development of antimicrobial treatments for respiratory pathogens in cystic fibrosis (CF) has been an integral component to the increased survival of CF patients over the past fifty years. Despite significant treatment advances, however, respiratory failure secondary to chronic bacterial pulmonary infection remains the primary cause of death in CF patients. The purpose of this review is to discuss emerging pathogens (ot Read More
-
-
-
Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Authors: Hartmut Grasemann and Felix RatjenThe concentrations of nitric oxide are decreased in airways of patients with cystic fibrosis. The reasons for this nitric oxide deficiency are incompletely understood but may include reduced production from nitric oxide synthases due to decreased expression, the enzymes in airway epithelial cells, reduced availability of L-arginine, the substrate for nitric oxide synthases, and the presence of endogenous inhibitors of t Read More
-
-
-
New Developments In Treatment After Lung Transplantation
Authors: Christian Benden, Lara Danziger-Isakov and Albert FaroLung transplantation has evolved as an accepted therapy in selected adults and children with end-stage lung disease. Outcomes following lung transplantation have improved in the recent era with a 5-year survival of >70% and an overall good functional status of surviving recipients. Many of the advances have been achieved by the use of modern immunosuppressive agents. To date, multiple strategies exist that may be e Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
